Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
Summary not available.
Summary not available.
Marietta, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, a leader in placental biologics, announced it will report its first-quarter financial results for the period ending March 31, 2023, on May 2, 2023, after market close. A conference call and webcast to discuss these results will follow at 5:00 p.m. Eastern Time. Investors can access the call through U.S. and international lines provided in the announcement. A replay will be available on the company’s website for 30 days post-event. MiMedx focuses on developing placental tissue allografts and has supplied over two million products to address clinical needs in advanced wound care and surgical recovery. The company is also advancing a late-stage pipeline targeting pain reduction and improved function for knee osteoarthritis patients.
MiMedx Group (Nasdaq: MDXG) announced the departure of CFO Peter M. Carlson on March 23, 2023, as he pursues other opportunities. The company has initiated a search for a new CFO, with Carlson assisting during the transition. His tenure at MiMedx significantly improved the company's finance and accounting, helping to raise debt and equity while avoiding delisting. MiMedx specializes in placental biologics, providing allografts for advanced wound care and surgical recovery. The company is committed to addressing unmet clinical needs and has delivered over two million allografts.
MiMedx Group, Inc. (MDXG) has praised the Office of Inspector General's recommendation for the Centers for Medicare and Medicaid Services (CMS) to expedite addressing issues related to Average Sales Price (ASP) reporting for skin substitute products. The OIG report highlights non-compliance from some manufacturers, impacting Medicare spending in private physician settings. MiMedx's products, EPIFIX® and EPICORD®, have been sold under transparent ASP-based rates, promoting equitable patient care. The report also encourages CMS to consider effective payment approaches and ensure compliance from manufacturers as a way to alleviate financial burdens on the Medicare Trust Fund.
MiMedx Group reported its highest quarterly net sales since Q4 2019, achieving $74.4 million in Q4 2022, a 10.3% increase year-over-year. For the full year, net sales reached $267.8 million, up 3.6%. Despite strong sales, the company faced a net loss of $0.4 million in Q4, compared to a net income of $2.2 million in the prior year. The gross margin decreased to 80.7% from 84.0%. MiMedx initiated its first registrational clinical trial for mDHACM targeting knee osteoarthritis, emphasizing growth potential in the Wound & Surgical segments. Future growth may depend on Medicare reimbursement changes.
MiMedx Group (Nasdaq: MDXG) will report its fourth quarter and full year financial results for the period ending December 31, 2022 after the market closes on February 28, 2023. A conference call and webcast led by the senior management team will follow at 5:00 p.m. ET on the same day to discuss the results.
The company is a leader in placental biologics, focusing on various healthcare sectors like Advanced Wound Care and knee osteoarthritis treatments. MiMedx has successfully supplied over two million allografts using its proprietary PURION® process.
MIMEDX (Nasdaq: MDXG) announced the appointment of Joseph H. Capper as its new Chief Executive Officer, effective immediately. Capper brings nearly 30 years of experience in MedTech, previously leading BioTelemetry through a successful turnaround that resulted in a $2.8 billion acquisition. The Board of Directors expressed confidence in Capper's leadership, citing his track record of delivering results. As part of his inducement package, he will receive 3.3 million performance stock units and 3.6 million stock options with an exercise price of $3.70. MIMEDX aims to leverage its innovative placental biologics for future growth.
Marietta, Ga., Jan. 09, 2023 – MiMedx Group (Nasdaq: MDXG) expects Q4 2022 net sales of $73M to $76M and full-year sales of $266M to $269M, unchanged since November 2022. The company commented on potential Medicare reimbursement changes impacting skin substitutes, accounting for 28% of sales, with 90% of these sales from EPIFIX. While uncertainties remain, MiMedx has taken steps to mitigate risks. Additionally, the company anticipates $5M in annual savings from recent restructuring and has entered a partnership for EPIFIX distribution in Japan.
MIMEDX has partnered with Gunze Medical to exclusively distribute EPIFIX in Japan, marking a significant move in the wound care market. This collaboration, announced on January 4, 2023, follows EPIFIX's regulatory approval and favorable reimbursement decision. Gunze Medical, backed by over 90 sales representatives, aims to leverage its existing clinician relationships to enhance awareness and sales. This partnership positions EPIFIX as the first and only amniotic tissue product approved in Japan for treating chronic wounds, targeting conditions like diabetic foot and venous leg ulcers.